Skip to main content

Oragenics, Inc.

corporate_fare Company Profile

Oragenics, Inc.

OGEN·NYSE·Life Sciences·CIK 0001174940

Oragenics, Inc. is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its lead product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid. It is lipophilic, and the company believes it can cross the blood-brain barrier with the goal of rapidly eliminating swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The company's lead product and focus are on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury ("mTBI" or "Concussion"). ONP-002, together with the company's other neurology assets, are referred to as the Neurology Assets. To date, ONP-002 has been shown to be stable up to 104 degrees for 18 months. The drug candidate is manufactured into a powder and filled into a novel intranasal device, and is then administered through the nasal passage from the device. The novel intranasal device is lightweight and easy to use in the field. The company believes the proprietary powder formulation and intranasal administration allows for rapid and direct accessibility to the brain. The device is breath propelled and is designed to allow patients to blow into the device, which closes the soft palate in the back of the nasopharynx, preventing the flow of drug to the lungs or esophagus, minimizing system exposure and side effects, and effectively crossing the blood brain barrier. This mechanism is designed to trap ONP-002 in the nasal cavity, allowing for more abundant and faster drug availability in the traumatized brain.

Oragenics, Inc. (NYSE:OGEN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 1 item for OGEN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 9/10. Recent SEC coverage for OGEN spans 10-Q.

Recent high-impact activity:

  • Oragenics 10-Q: Going Concern Doubt, ONP-002 Enrollment Paused, $2.2M Cash Lasts to Year-End

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$9.84M
Diluted EPS
-$4.56
Op. Cash Flow
-$9.25M
Operating Income
-$9.36M
Cash & Equivalents
$4.4M
Debt / Equity
0.00×
Shares Outstanding
4.27M sh
Source: 10-K · filed 2026-03-16 · accession 0001493152-26-010282

Short Interest & Short Volume

40.07 days to cover

FINRA reported short interest of 835,778 shares in OGEN as of the October 30, 2026 settlement, a 0.1% decrease from the prior period — about 40.1 days to cover at its recent average daily volume. On November 20, 2026, 14.7% of OGEN volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)835,778 shares as of October 30, 2026
Change vs prior period▼ 0.1%
Days to cover40.07 at avg daily volume of 20,858
Daily short volume (FINRA facilities)14.7% of 107,515 shares on November 20, 2026
5-day average short volume23.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

$0.1576 +0.38% today
52-week range · as of 2026-11-12 $0.1576 – $1.22
Market cap
$708.38K
Volume
327K (0.2× avg)
3-mo avg 1.8M
Live data · 2026-11-22 05:59 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed OGEN - Latest Insights

OGEN
Nov 12, 2026, 5:12 PM EST
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.333
Real-time Price: $0.1576 info
Change: -$0.1754 (-53%) info
Market Cap: $708.377K info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets